Human papillomavirus genotype distributions: Implications for vaccination and cancer screening in the United States

Journal of the National Cancer Institute

Volumn 101, Issue 7, 2009, Pages 475-487

  Wheeler, Cosette M ^a,d   Hunt, William C ^a   Joste, Nancy E ^a   Key, Charles R ^a   Quint, Wim G V ^b   Castle, Philip E ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b DDL DIAGNOSTIC LABORATORY   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER INVASION; CANCER PATIENT; CANCER RISK; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; UNITED STATES; UTERINE CERVIX CANCER; VIRUS INFECTION; ADENOCARCINOMA; AGED; ALPHAPAPILLOMAVIRUS; CANCER REGISTRY; CANCER STAGING; CARCINOMA; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; GENETICS; HISPANIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; STATISTICS; UTERINE CERVIX TUMOR; VIROLOGY;

CANCER VACCINE; WART VIRUS VACCINE;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CANCER VACCINES; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HISPANIC AMERICANS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LOGISTIC MODELS; MASS SCREENING; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEW MEXICO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREDICTIVE VALUE OF TESTS; PREVALENCE; RESEARCH DESIGN; RISK ASSESSMENT; SEER PROGRAM; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 63649116323     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn510     Document Type: Article

References (51)

1. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819.
2. Schwartz SM, Daling JR, Shera KA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001;19(7):1906-1915.
3. Munoz N, Bosch FX, de Sanjosâe S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
4. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a metaanalysis update. Int J Cancer. 2007;121(3):621-632.
5. Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst. 1996;88(19):1361-1368.
6. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1808-1816.
7. Samet JM, Wiggins CL, Key CR, Becker TM. Mortality from lung cancer and chronic obstructive pulmonary disease in New Mexico, 1958-82. Am J Public Health. 1988;78(9):1182-1186.
8. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl. 1994;3(6):S113-S122.
9. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
10. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001;183(11): 1554-1564.
11. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-19.
12. Kleter B, van Doom LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998; 153(6):1731-1739.
13. Kleter B, van Doom LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37(8):2508-2517.
14. Van Doom L-J, Quint W, Kleter B, et al. Genotyping of human papillomavirus by the PGMY-line blot and the SPF10-line probe assay in liquid cytology cervical specimens. J Clin Microbiol. 2002;40(3):979-983.
15. Castle PE, Porras C, Quint WG, et al. A comparison of two PCR-based human papillomavirus genotyping methods [published online ahead of print August 20, 2008]. J Clin Microbiol. 2008;46(10):3437-3445.
16. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. A comparison of linear array and line blot assay for detection of HPV and cervical precancer and cancer in the ASCUS LSIL triage study. J Clin Microbiol. 2008;46(1): 109-117.
17. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen HH. Classification of papillomaviruses. Virology. 2004;324(1): 17-27.
18. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76-84.
19. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
20. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial [published erratum appears in Lancet. 2007;370(9596):1414].
21. Lancet. 2007;369(9580):2161-2170.
22. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006-,66(20)-10112-10119.
23. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, November 2004 submission (1973-2003). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2006, based on the November 2005 submission. Available at: http://www.seer.cancer. gov. Accessed November 26, 2008.
24. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, eds. SEER Summary Staging Manual-2000: Codes and Coding Instruactions. Bethesda, MD: National Cancer Institute; 2001. NIH Pub. No. 01-4969.
25. Bulkmans NW, Bleeker MC, Berkhof J, Voorhorst FJ, Snijders PJ, Meijer CJ. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer. 2005;117(2): 177-191.
26. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of highgrade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst. 2002;94(18):1406-1414.
27. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control. 2003; 14(9):805-814.
28. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68(1):307-313.
29. de Cremoux P, de la Rochefordière A, Savignoni A et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer. 2009; 124(4)778-782.
30. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007; 127(5):805-815.
31. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91(3):252-258.
32. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference, [published erratum appears in J Low Genit Tract Dis. 2008;12(1):63].
33. J Low Genit Tract Dis. 2007;11(4):223-239.
34. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489-498.
35. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing [review]. Cancer. 2007;111(3):145-153.
36. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination [review]. Vaccine. 2008 Mar 14;26 (suppl 1):A16-A23.
37. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and costeffectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604-615.
38. Sawaya GF, Washington AE. Cervical cancer screening: which techniques should be used and why? Clin Obstet Gynecol. 1999;42(4):922-938.
39. Leyden WA Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675-683.
40. Jeronimo J, Massad LS, Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. 2007;197(l):47.e41-47.e48.
41. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79(3):328-337.
42. Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapidonset cervical cancer. Am J Obstet Gynecol. 1999; 180(3):571-577.
43. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
44. Smith HO, Tiffany MF, Quails CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States- a 24-year population-based study. Gynecol Oncol. 2000;78(2):97-105.
45. Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191-2199.
46. LaceyJVJr, Brinton LA, Abbas FM, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1079-1085.
47. Lacey JV Jr, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol. 2000;77(1):149-154.
48. Lacey JV Jr, Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003;98(4):814-821.
49. Sargent A, Bailey A Almonte M, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. BrJ Cancer. 2008;98(10):1704-1709.
50. Health Protection Agency. Health Protection Report. 2007; 1(35). Health Protection Agency; 2007.
51. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1611-1622.